1 to 9 of 22 results

Sanofi showcases next wave of medicines and vaccines


French pharma major Sanofi is today outlining its intention to launch high-potential new medicines and…

Cardio-vascularDiabetesHealth Medical PharmaImmunologicalsNeurologicalPharmaceuticalPharmaceutical industryRare diseasesResearchSanofiUnited StatesVaccines

Added indications recommended by EMA/CHMP

Added indications recommended by EMA/CHMP


Along with backing for approval for six news drugs issued at the late June meeting of the European Medicines…

AvastinBayerBristol-Myers SquibbCardio-vascularEliquisEuropeEyleaKalydecoOncologyOphthalmicsPfizerPharmaceuticalRare diseasesRegulationRocheVertex Pharmaceuticals

More positive Ph III data for Amgen’s evolocumab

More positive Ph III data for Amgen’s evolocumab


Leading independent biotech firm Amgen has released more positive clinical trial data with its cholesterol…

AmgenBiotechnologyCardio-vascularevolocumabRare diseasesResearch

Retrophin to acquire Manchester Pharma in $62.5 million deal

Retrophin to acquire Manchester Pharma in $62.5 million deal


USA-based Retrophin has signed an agreement to acquire Manchester Pharmaceuticals, a privately-held specialty…

Cardio-vascularChenodalManchester PharmaceuticalsMergers & AcquisitionsPharmaceuticalRare diseasesRetrophinVecamyl

Aegerion gains European approval for rare disease drug


The European Commission has approved US biopharma company Aegerion Pharmaceuticals' (Nasdaq: AEGR) Lojuxta…

Aegerion PharmaceuticalsBiotechnologyCardio-vascularEuropeJuxtapidKynamroLojuxtalomitapidePharmaceuticalRare diseasesRegulation

US FDA accepts Ruconest filing from Santarus and Pharming


US drugmaker Santarus (Nasdaq: SNTS) and Netherlands-based Pharming Group (NYSE Euronext: PHARM) say…

BiotechnologyCardio-vascularNorth AmericaPharmingRare diseasesRegulationRuconestSantarus

US FDA accepts NDAs for Otsuka's tolvaptan and BTG's Varisolve


Japanese mid-sized drugmaker Otsuka Pharmaceutical (TYO: 4578) says that the US Food and Drug Administration…

BTGCardio-vascularNephrology and HepatologyNorth AmericaOtsukaPharmaceuticalRare diseasesRegulationtolvaptanVarisolve

FDA clears Sanofi and Isis' Kynamro for inherited cholesterol disorder


The US Food and Drug Administration yesterday approved Sanofi (Euronext: SAN) subsidiary Genzyme's orphan…

BiotechnologyCardio-vascularGenzymeIsis PharmaceuticalsKynamroNorth AmericaPharmaceuticalRare diseasesRegulationSanofi

1 to 9 of 22 results

Back to top